ULUSLARARASI KONGRE BİLDİRİLERİ


1-Berkol B, Köksal M, Uysal A, Küçükali Y, Çınar Y, ONAT H, Ruacan Ş. A case of mast cell leukemia with severe bleeding.
International İstanbul Symposia on Hematology, 1981.

2- Berkol B, ONAT H. An interesting case of idiopathic thrombocytopenic purpura coexiting with hyperthyroidism.
Meeting of the Mediterranean blood club, 9-12 june 1984, İzmir, Turkey.

3- İnceman Ş, Tangün Y, Pekçelen Y, Atamer T, Sargın D, ONAT H. Treatment of acute non-lymphoblastic leukemia with low dose cyrabine, studies on 40 cases.
15 th International Congress of Chemotherapy, 19-24 July 1987, İstanbul, Turkey.

4- Akın C, Kaya G, ONAT H, Mardinli B, Altuğ T, Devrim S. The effect of Bestatin on Mitomycin- C induced myelosupression.
Third Congress of the Mediterrenean Society of Therapy, 12-15 September 1988, Barcelona, Spain

5- Aykan NF, Bilge N, ONAT H, Kınay M, Topuz E, Dinçol K. Le role de prognostic des transfusion sanguines dans la maladie de Hodgkin
Symposium biologie des lymphomes malins humains, 5-6 mars 1990, Bordeaux, France

6- ONAT H, Yasasever V, Ekşinozlugil Z, Dalay N. Osteocalcin: a valuable bone metastasis marker
15 th International Cancer Congress, 16-22 August 1990 1990, Hamburg, Germany J Cancer Res Clin Oncol 116: 261, 1990.

7- Yasasever V, Bilge N, Töre G, ONAT H, Enginün M. Menstrual cycle values of tumor marker in healty women and in patients with non-gynecological tumor.
15 th International Cancer Congress, 16-22 August 1990 Hamburg, Germany J Cancer Res Clin Oncol 116: 262, 1990.

8- Yasasever V, ONAT H, Aykan F, Ekşinozlugil Z. Antithrombin III plasma levels in cancer patients.
15 th Interantional Cancer Congress, 16-22 August 1990 Hamburg, Germany. J Cancer Res Clin Oncol 116: 632, 1990.

9- Aykan NF, ONAT H, Tunç M, Kınay M, Uysal V, Ağan M, Bilge. Le traitement de I'interferon alpha recombinant permettant la resectabilite chez un cas de cancer du rein inoperable
Third International Congress on Neo- Adjuvant Chemottherapy 6-9 February 1991, Paris, France.

10- Bilge N, Kınay M, ONAT H. The undergraduate oncology education in İstanbul Medical Faculty
4 th Annual Scientific Meeting of European Association fo Cancer Education , 24-27 April 1991.

11- Yasasever V, ONAT H, Şengün Z, Dalay N. The value of CA 72.4 in patients with gastrointestinal tumors and comparison with CEA and CA 19-9.
FERS Advanced Course "Oncogenes and Cell Growth", Kiev, USSR.

12- Yasasever V, Şengün Z, Şaydan N, ONAT H, Dalay N. The value of CA 72.4 in patients with gastrointestinal tumors
International Union of Biochemistry Commitee on Education Meeting on Modern Biochemical Science, 11-17 August 1991, İzmir, Turkey.

13- Baltalı E, İçli F, ONAT H, Mandel N, Berk Ö, Ober A. Phase II study of weekly doses of Epirubicin breast cancer.
6 th European conference on clinical oncology and cancer nursing 28-31 October 1991. Florence, Italy Eur J Cancer Supp 2: 559, 1991.

14- ONAT H, Altun M, Bilge N, Karadeniz A, Ertürk N, Aydıner A, Aykan F. Chemotherapy and radiotherapy for locally advanced undifferentiated nasopharyngeal carcinoma.
IV Interanational IST Symposium on Interaction of chemotherapy in solid tumors. 13-15 April 1992, Genoa, Italy.

15- Altun M, Topuz E, ONAT H, Aldemir O, Bilge N, Darendeliler E, Kınay M. Adjuvant Cisplatin based chemotherapy for oco- regionally advanced undifferentiated nasopharyngeal carcinoma.
IV International IST Symposium on chemotherapy and radiotherapy in solid tumors, 13-15 April 1992, Genoa, Italy.

16- Darendeliler E, ONAT H, Kınay M, Çakmak M, Kurul S, Bilge N. Concomittant continuous infussion epirubicin and Hyperfractionated radiotherapy in locally advanced soft tissue sarcomas.
IV International IST symposium on Inteaction of chemotherapy and radiotherapy in solid tumors, 13-15 April 1992, Genoa, Italy.

17- Darendeliler E, Ayan İ, Kebudi R, Altun M, Ağaoğlu L, Kınay M, ONAT H, Bilge N. Neoadjuvant chemotherapy and radiotherapy in children with nasopharyngeal carcinoma.
IV International IST Syymposium on Interaction of chemotherapy in solid tumors, 13-15 April 1992, Genoa, Italy.

18- Dalay N, Yazıcı H, ONAT H. BCL-2 rearrangemants in Turkish lymphoma patients.
5 th International Congress on cell biology 26-31 July 1992, Madrid, Spain.

19- Yasasever V, Karaloğlu D, Yazıcı H, ONAT H, Dalay N. Serum and Tissue Neu Oncoprotein levels in turkish breast cancer patients.
5 th International Congress on cell biology 26-31 July 1992, Madrid, Spain.
v20- Aykan NF, Dinçol K, Hamamizade M, Yağcı T, ONAT H, Bilge N. The effects of adjuvant modified CMF chemotherapy on some immunological parameters in breast cancer patients.
9 th Interanional Congress of Endocrinology, hormones and Breast cancer, 29-30 August 1992, Nice, France.

21- Yağcı T, Ekmekçioğlu S, İnanç SE, ONAT H. Natural killer cell activity in the patients with malignant lymphoma.
4 th Interanational Conference of Anticancer Research, 21-25 October 1992, Grete, Greece.

22- Aydıner A, ONAT H, Öztürk N, Aykan F, İnanç S, Topuz E, Dinçok K. The efficacy of a drug antiemetic regimen on the consequent cisplatin containing chemoterapies.
Congress of European Society of Medical Oncology (ESMO) 7-10 November 1992, Lyon, France

23- Aykan NF, Dinçol K, Hamamizade M, Yağcı T, ONAT H, Bilge N. The effect of adjuvant modified CMF chemotherapy on some immunological parameters in breast cancer.
Congress of European Society of Medical Oncology (ESMO) 7-10 November 1992, Lyon, France.

24- Aykan NF, Ayyıldız M, Aksoy M, Yağcı T, ONAT H, Bilge N. The effect o-562.f benzene on P-gyycoprotein expression in the leukumic cell lines HL, 60 and K
Congress of European Society of Medical Oncology (ESMO) 7-10 November 1992, Lyon, France.

25- ONAT H, Aydıner A, İnanç ES, Dinçol K, Topuz E. Crossover trial of Ondansetron and Ondansetron plus dexamethasone as antiemetic prophylaxis during Cisplatin containing chemotherapy.
Congress of European Society of Medical Oncology (ESMO) 7-10 November 1992, Lyon, France.

26- ONAT H, İnanç ES, Acarlar K, Ander H, Topuz E, Bilge N. Achieving resectability in operable, locally advanced renal cell caarcinoma with a combination of fluouracil and Interferon.
4th International Congress on anticancer chemotherapy, 2-5 February 1993, Paris, France.

27- Darendeliler E, ONAT H, Inanç ES, Kurul S, Erseven G, Aktan G, Riggi M, Topuz E, Bilge N. Hyperfractionad radiotherapy and concomitant continous ınfussion epirubicin in locally advanced soft tissue sarcomas.
29th annual meeting of American Society of Clinical oncology (ASCO) 16-18 May 1993, Orlando, Florida, USA.

28- İnanç ES, ONAT H, Dinçol K. Cardiotoxicity and Fluouracil
18th International Congress of Chemotherapy 27 June- 2 July 1993, Stockholm, Sweden .

29- Özger H, Eralp L, Darendeliler E, ONAT H. The role of hyperfractionated radiotherapy, concomitant continous infusion Epirubicin and surgery in the treatment of locally advanced soft tissue sarcomas.
7th International Symposium of Limb Salvage 23-27 August 1993, Singapore.

30- Aykan NF, Bilge N, Topuz E, Aldemir O, Dinçok K, Dinçer M, ONAT H, Salepçi T. The efficacy of combining interferon alfa with cisplatin in previously cisplatin resistant squamous cell lung cancer.
lst Interantional Conference on Reversal of Multidrug Resistance in Cancer, 1-3 September 1994 St Gallen, Switzerland.

31- ONAT H, İnanç ES, Pişkin S, Aracı A, Topuz E. Myloprotective effect of GM-CSF administered priop to chemotherapy
30th annual meeting of American Society of Clinical Oncology (ASCO) 13: 1537, 1994.

32- Topuz E, Aydıner A, Saip S, İnanç S, Aslay I, Aykan NF, ONAT H. Intraperitoneal chemotherapy in patients with primary ovarian cancer.
30th annual meeting of American Society of Clinical Oncology (ASCO) 13: 1537, 1994.

33- Aykan NF, Aydıner A, Ertürk N, ONAT H, Topuz E, Dinçer M, Karadeniz A, Bilge N. The prognostic value of adjuvant chemotherapy timing and dose intensity in early breast cancer.
9th Mediterrenean congress of Chemotherapy 12-17 June 1994, Milano, Italy.

34- Baltalı E, İçli F, Molinas NM, ONAT H, Aktan G, Öber A, Üskent N, Kınay M, Berk Ö, Fırat D. Neoadjuvant weekly Epirubicin Chemotherapy ol locally advanced breast cancer.
16th International Cancer Congress 30 October- 5 November 1994, New Delhi, India.

35- Dinçol D, Mandel Molinas N, Barışta İ, Aktan G, ONAT H, Sardaş OS, Berk Ö, Çehreli C, Fırat D. Weekly Epirubicin in combination chemotherapy in the treatment of intermediate and high grade Non- Hodgkin lymphoma.
16th International Cancer Congress 30 October- 5 November 1994, New Delhi, India.

36- İnanç ES, ONAT H, Aydıner A, Altun M, Oral EN, Bilge N, Topuz E. Cisplatin, fluorouracil and alpha 2b interferon for recurrent or metastatic head and neck cancer.
16th International Cancer Congress 30 October- 5 November 1994, New Delhi, India.

37- Berk O, ONAT H, Kars A, Serdengeçti S, Günel N, Aykan F, Okkan S, Kınay M, Üskent N, Aktan G. High dose Epirubicin and Ifosfamide alternating with Etoposide and cisplatin therapy with GM-CSF in small cell lung v,cancer.
19th Congress of the European Society for Medical Oncology 18-22 November 1994, Lisbon, Portugal.

38- İnanç ES, ONAT H, Darendeliler E, Bilge N, Öztürk N, Topuz E. CEOP regimen in the treatment of aggressive Non Hodgkin's lymphomas
19th Congress of the European Society for Medical Oncology 18-22 November 1994, Lisbon, Portugal.

39- Wierzbicki R, Cvitkovic E, El Gueddari I, ONAT H, Habboubi N, Riva A, Benhamou E, Armand JP, Fountzilas G, Kosmidis P, Mrsic Z, Oliveria J, Rahal M, Prasad U, Fandi A, Eschwege F. Neoadjuvant chemotherapy with Epirubicin, Cisplatin, Bleoycin in undifferentiated nasopharyngeal cancer.
19th Congress of the European society for Medical Oncology 18-22 November 1994, Lisbon.

40- Aydıner A, Saip P, Topuz E, Dinçok K, ONAT H. Risk factors influencing emesis for patients undergoing cisplatin based chemothearpy.
19th Congress of the European society for Medical Oncology 18-22 November 1994, Lisbon.

41- Topuz E, Aydıner A, Saip P, Aykan F, ONAT H, Karadeniz A. A phase II trial of divided Epirubicin dosage in combination therapies with Gm-CSF for small cell lung cancer.
19th Congress of the European society for Medical Oncology 18-22 November 1994, Lisbon.

42- ONAT H, İnanç ES, Saip P, Topuz P. Tropisetron in the prevention of emesis associated with multiple day cisplatin based chemotherapy.
5th International Congress on Anti-Cancer chemotherapy 31 January- 3 February 1995, Paris, France.

43- İnanç ES, ONAT H, Oğuz H, Topuz E. Autoimmune phenomena in patients receiving alpha interferon therapy.
5th International Congress on Anti-Cancer chemotherapy 31 January- 3 February 1995, Paris, France.

44- Topuz E, Saip P, Aydıner A, İnanç S, ONAT H, Aykan F. Phase II study of Cisplatinum, fluorouracil and Calcium folinate combination in Antracyline resistant metastatic breast cancer.
5th International Congress on Anti-Cancer chemotherapy 31 January- 3 February 1995, Paris, France.

45- ONAT H, İnanç SE, Saip P, Topuz E. Tropisetron in the prevention of emesis associated with 5 day cisplatin based chemotherapy in patients with germ cell tumors.
31st annual meeting of American Society of Clinical Oncology (ASCO) 20-23 May 1995. Los Angeles, USA.

46- Saip P, ONAT H, İnanç ES, Topuz E. Interferon alpha 2b in advanced renal cell cancer.
19th Interantional Congress of Chemotherapy 16-21 July 1995, Montreal, Quebec, Canada.

47- Saip P, ONAT H, İnanç ES, Topuz E. Ondansetron and domperidon in patients receiving 3 courses of FEC for breast cancer.
7th International Symposium Supportive Care in Cancer 20-23 September 1995, Luxembourg.

48- İnanç SE, ONAT H, Adalet K, Yasasever V, Karaloğlu D, Dalay D, Topuz E. Fluorouracil cadiotoxicity and coagulation parameters.
32st annual meeting of American Society of Clinical Oncology (ASCO) 18-21 May 1996, Philadelphia, USA. Rroc ASCO 15: 537, 1996 (Abst 1743)

49- ONAT H, İnanç S, Darendeliler E, Özger H, Çakmaklı M, Erseven G. Neoadjuvant chemotherapy and climb- spaning surgery in osteosarcoma.
21st Congress of the European Society of Medical Oncology 1-5 November 1996, Vienna, Austria.

50- ONAT H, Esassolak M, İnanç S, Haydaroğlu A, Altun M. High dose Epirubicin and cisplatinum in locally advanced undifferentiated nasopharyngeal carcinoma.
21st Congress of the European Society of Medical Oncology 1-5 November 1996, Vienna, Austria. Ann Oncol 7 (Supp 5): 82, 1996

51- Aykan NF, Üskent N, Yaylan M, Güllü İ, Çamlıbel S, Ertürk N, Dişçi R, ONAT H. 5 Fluorouracil plus interferon alfa -2 B versus 5 Fluorouracil plus folinic acid in advanced colorectal cancer.
21st Congress of the European Society of Medical Oncology 1-5 November 1996, Vienna, Austria. Ann Oncol 7 (Supp 5): 42, 1996.

52- ONAT H, Saip P, İnanç SE, Darendeliler E. Etoposide, mitoxantone, ifosfamide combination chemotherapy in the treatment of refractory and relapsed non Hodgkin's lymphoma.
7th International Congress on anticancer treatment 3-6 February 1997, Paris, France.

53- Salepçi T, İnanç SE, Saip P, ONAT H. Results of empirical antimicrobial therapy in cancer patients with neutropenic fever.
7th International Congress on anticancer treatment 3-6 February 1997, Paris, France.

54- İnanç SE, Meral R, ONAT H, Yasasever V, Darendeliler E. The prognostic significance of marker half life during chemotherapy for seminamatous germ cell tumors.
33rd annual meeting of American Society of Clinical oncology (ASCO), 17-20 May 1997, Denver, Colorodo, USA. Proc ASCO 16: ..... 1997 (Abst

55- İnanç SE, ONAT H, Darendeliler E, Çamlıca H, Kalaycı G. Prolonged survival with complete resection of lung metastasis
ECCO 9 European Cancer Congress, 14-18 September 1997, Hamburg, Germany. Eur J Can 33 ( Supp 8): 5117, 1997 (Abst 522)

56.- Saip P, Yasasever V, Tenekeci N, Aydıner A, Inanç S, ONAT H, Topuz E. The biochemical marker changes in assessment of radiological response of breast cancer patients with bone metastases.
8th Intenational Congress on Anti-Cancer Treatment, 3-6 February 1998, Paris, France

57- Inanç S, Yazıcı H, Saip P, ONAT H, Dalay N. Bcl-2 gene rearrangement and apoptosis in diffuse large cell lymphoma: Correlation with prognostic factors and survival
34th Annual meeting of American Society of Clinical Oncology (ASCO), 16-19 May 1998, Los Angelos, California, USA Proc ASCO 17: 27, 1998

58- ONAT H Esassolak M, İnanç ES, Sanacak Y, Başaran M, Haydaroğlu A, Altun M, High dose Epirubicin and Cisplatinum in locally advanced undifferentiated nasopharyngeal carcinoma.
3rd Educational Convention of the European School of Oncology, Lingotto, Turin, Italy, 28-30 May 1998 (Abst OP 155)

59- Saip P, Inanç SE, ONAT H Salvage Mesna, Ifosfamide, Mitoxantrone, Etoposide combination in Non-Hodgkin’s Lymphoma.
2nd Balkan Oncology Congress, Kuşadası, Turkey, 10-14 September 1998

60- Kurul S, İnanç S, ONAT H, Darendeliler E Soft tissue sarcomas
2nd Balkan Oncology Congress, Kuşadası, Turkey, 10-14 September 1998

61- Saip P, ONAT H, Başaran M, Taş F, Demir C, Uygun K, Topuz E Clinical efficacy of diazepam in prophylaxis of acute and delayed emezis induced by cisplatin based chemotherapy.
23rd ESMO Cngress, Athens, Greece, 6-10 November 1998 Ann Oncol 9(supp 4):146, 1998

62- Demirkazık A, ONAT H, Saip P, Özgüroğlu M, Kars A, Çay F, Demir G, Üner A, F.Arpacı, Aktan G. High dose Epirubicin and Cisplatin induction chemotherapy sequentially followeed by Ifosfamide and Etoposide chemotherapy in extensive stage small cell lung cancer.
23rd ESMO Cngress, Athens, Greece, 6-10 November 1998 Ann Oncol 9(supp 4):105, 1998

63- Çay F, ONAT H, Saip P, Kars A, Demirkazık A, Akbulut H, Koca S, Akyol F, Aktan G, Fırat D. Cisplatin and Epirubicin induction chemotherapy followed by chemoradiotherapy in limited stage small lung cancer.
23rd ESMO Cngress, Athens, Greece, 6-10 November 1998 Ann Oncol 9(supp 4):104, 1998

64- İnanç SE, Alıcı S, Saip P, Kurul S, ONAT H High dose Ifosphamide in refractory, recurrent and metastatic sarcoma.
23rd ESMO Congress, Athens, Greece, 6-10 November 1998 Ann Oncol 9(supp 4):118, 1998

65- Alıcı S, Bavbek ES, Başaran M, Çamlıca H, ONAT H Prognostik factors and long term follow up in Aggressive Non-Hodgkin’s lymphoma.
35th Annual Meeting American Society of Clinical Oncology (ASCO), 15-19 May 1999, Atlanta, Georgia, USA. Proc ASCO 18:38, 1999 (Abst 143).

66- Başaran M, Bavbek ES, Uygun K, Darendeliler E, ONAT H Adult Ewing’s Sarcoma of the axial sysytem:Dismal prognosis despite intensive multiagent chemotherapy.
35th Annual Meeting American Society of Clinical Oncology (ASCO), 15-19 May 1999, Atlanta, Georgia, USA. Proc ASCO 18:550, 1999 (Abst 2123).

67- Salepci T, Yazıcı H, Topuz E, Dalay N, ONAT H Detection of Human Papillomavirus (HPV) DNA in human colorectal cancer.
35th Annual Meeting American Society of Clinical Oncology (ASCO), 15-19 May 1999, Atlanta, Georgia, USA. Proc ASCO 18:618, 1999 (Abst 2389).

68- Yaman F, Altun M, Altin S, Tenekeci N, Bavbek S, ONAT H Continous hyperfractionated accelareted radiation therapy (chart) with fotemustine for malignant gliomas.
10th European Conference of Clinical Oncology, 11-14 Sept 1999, Vienna, Austria Eur J Cancer 35(Supp 4):121, 1999

69- Bavbek ES, Başaran M, Uygun K, Alici S, Darendeliler E, ONAT H Cyclophosphamide, vincristine, epirubicin and prednisolon (CEOP-100) in aggresive NonHodgkin’s lymphoma.
10th European Conference of Clinical Oncology, 11-14 Sept 1999, Vienna, Austria Eur J Cancer 35(Supp 4):337, 1999

70- Başaran M, Bavbek ES, Alici S, Uygun K, Dogan Ö, Agan M, Darendeliler E, ONAT H Prognostic factors in primary gastric non Hodgkin’s lymphoma.
10th European Conference of Clinical Oncology, 11-14 Sept 1999, Vienna, Austria Eur J Cancer 35(Supp 4):337, 1999

71- Eralp Y, Bavbek ES, Başaran M, Uygun K, Kaytan E, Çamlıca H, Darendeliler E, ONAT H Survival and prognostic factors in patients with Hodgkin’a disease. v10th European Conference of Clinical Oncology, 11-14 Sept 1999, Vienna, Austria Eur J Cancer 35(Supp 4):338, 1999

72- ONAT H, Bavbek ES, Uygun K, Başaran M, Kılıcarslan I, Uysal V, Özcan F, Tunc M Surveillance and adjuvant chemotherapy in clinical stage I nonseminomatous testicular cancer.
10th European Conference of Clinical Oncology, 11-14 Sept 1999, Vienna, Austria Eur J Cancer 35(Supp 4):351, 1999

73- Alici S, Kaytan E, Basaran M, Bavbek ES, Darendeliler E, ONAT H. Effect of age on the characteristics and clinical behavior of Non-Hodgkin’s lymphoma patients.
Proc ASCO 19:39, 2000 (Abstr 146).

74- Basaran M, Hafiz G, Sakar B, Eralp Y, Bavbek ES, Darendeliler E, ONAT H Hearing loss in testicular cancer patients treated with bleomycin, etoposide and cisplatin combination.
Proc ASCO 19:39, 2000 (Abstr 1438).

75- ONAT H, Basaran M, Güllü I, Demirelli F, Sakar B, Bavbek ES. Preliminary results of a phase II study of paclitaxel and cisplatin in recurrent or metastatic head and neck cancer.
Proc ASCO 19:39, 2000 (Abstr 1694D).

76- Bavbek S, Başaran M, Saip S, Eralp Y, Sakar B, ONAT H Neurologic late toxicity in testicular cancer patients treated with bleomycin, etoposide and cisplatin combination chemotherapy.
25th ESMO Congress, Hamburg, Germany, 13-17 November, 2000 Ann Oncol 11(Supp 4):78, 2000

77- Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Bilgiç B, Darendeliler E, ONAT H Prognostic factors and survival in adult patients with small round cell tumors
25th ESMO Congress, Hamburg, Germany, 13-17 November, 2000 Ann Oncol 11(Supp 4):126, 2000

78- Başaran M, ONAT H, Bavbak S, Argon A, Yaman F, Esen T, Uysal V Review of management in extragonadal germ cell tumors in adult patients.
Proc ASCO 20:158, 2001

79- Bavbek S, ONAT H, Üstüner Z, Başaran M Oral combination chemotherapy with etoposide, chlorambucil and prednisolone for recurrent and refractory lymphoma.
Proc ASCO 21:204, 2002

80- Alıcı S, Bavbek S, Kaytan E, Eralp Y, Argon A, ONAT H Prognostic factors in localized aggressive non-Hodgkin’s lymphoma.
Proc ASCO 21:206, 2002

81- Carteni G, Dogliotti E, Crucitta A, Martoni S, ONAT H, Bertetto O, Bono A, Amadori D Phase II randomized trial of gemcitabine plus cisplatin and gemcitabine plus carboplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelium
29th Annual meeting American Society of Clinical Oncology, 31 Mayıs-3 Haziran 2003, Chicago, Illiniois, ABD Abstr 1543

82- Bavbek ES, Yazar A, Başaran M, ONAT H Prognostic factors for survival in metastatic renal cell carcinoma: Experience from a single institute
29th Annual meeting American Society of Clinical Oncology, 31 Mayıs-3 Haziran 2003, Chicago, Illiniois, ABD Abstr 1750

83- Çamlıca H, Rian Dişci, ONAT, H, Topuz E “The catchment area of cancer patients of Istanbul University Oncology Institute”
31st ESMO Congress, Istanbul, Turkey, 29 September – 3 October 2006 Ann Oncol 17:(Supp 9)(Abst 133), 2006

84- Bavbek S, Derin D, Öztürk B, başaran M, ONAT, H “Feasibility of close surveillance in stage I Nonseminomatous testicular germ cell cancer: Single Institution wxperience”
Ann Oncol 17:(Supp 9) (Abst 409), 2006